Moisson Montréal Rolls Out the Red Carpet and Awards $2 Million in Grants to 69 Heroes of Food Assistance
MONTREAL, May 27, 2025 (GLOBE NEWSWIRE) — This morning at the Jean-Talon Market, where it all began 40 years ago, Moisson Montréal concluded its 40th anniversary celebrations by awarding $2,048,311 in grants to 69 community agencies. These grants will fund the purchase of basic equipment like refrigerators, cold storage units, vehicles, crates, and tables, essential and concrete tools to better nourish Montrealer's living in precarious situations.
To mark this important gesture, Moisson Montréal symbolically rolled out a red carpet. Not to celebrate prestige, but to honor those who, far from the spotlight yet at the heart of the action, work every day to support the most vulnerable.
'This isn't a glamorous event. What we are awarding today are fridges, stoves, and trucks. But behind each of these pieces of equipment lies an essential gesture toward food dignity. Today, we are celebrating the real heroes working in the frontline,' said Chantal Vézina, Executive Director of Moisson Montréal.
A Powerful Response to Pressing Needs
A total of 162 project proposals were received, reflecting a community sector under strain — rich in ideas but limited by resources. The high quality of submissions highlighted the scale of needs: outdated or missing basic equipment, spaces needing renovation, and delivery capacity to be strengthened. More than $5 million would have been needed to fund all submissions.
The selection was carried out by an independent committee composed of individuals from diverse backgrounds in food security, applying rigorous criteria to prioritize project diversity, tangible impact, and territorial equity.
'We received solid, meaningful, human proposals. The selection process was heart-wrenching. Most of the projects deserved funding. That's why our Board of Directors decided to extend funding beyond the initial plan,' added Ms. Vézina.
A Gesture Made Possible Thanks to The Rossy Foundation
The grants were made possible through a major philanthropic donation from The Rossy Foundation, bolstered by a vote from Dollarama employees who helped direct The Rossy Foundation's funding to Moisson Montréal. This collective gesture raised $1.3 million, which was supplemented by Moisson Montréal's own funds.
A Map Showcasing Impact Across All Boroughs
A geographic map installed onsite allows visitors to visualize the projects supported throughout Montreal's boroughs. Each point represents a concrete solution driven by a community-based organization.
This morning, 69 faces of resilience walked the red carpet. No trophies. Just everyday heroes feeding the vulnerable.
For more information, please contact:
Éliane LaroucheSenior Advisor, Communications and Public AffairsMoisson Montréal514 701-4206
[email protected]
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
2 hours ago
- Associated Press
Artelo Biosciences Announces Positive First-in-Human Data for ART26.12, a Novel Non-Opioid Treatment Candidate for Persistent Pain
First Orally Active Fatty Acid Binding Protein 5 Inhibitor Evaluated in Humans First-in-Class Approach Targets Unmet Need in Multibillion-Dollar Pain Management Market SOLANA BEACH, Calif., June 30, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, dermatological or neurological conditions, today announced favorable results from its first-in-human study evaluating ART26.12, a novel inhibitor of Fatty Acid Binding Protein 5 (FABP5). The results affirm the promising safety and pharmacokinetic (PK) profile previously observed in preclinical studies. Inhibiting FABP5 represents a unique mechanism of action with ART26.12 standing out as a first-in-class candidate in the field of pain management. The Phase 1 Single Ascending Dose (SAD) study was designed to assess the safety, tolerability, and pharmacokinetics of ART26.12 in healthy volunteers. The SAD study enrolled 49 subjects. The key findings include: Andrew Yates, Ph.D., Senior Vice President and Chief Scientific Officer at Artelo, commented, 'We are greatly encouraged with the results of the SAD study with our lead FABP5 inhibitor and we are particularly pleased to observe that the safety and PK profile that had been generated from ART26.12's non-clinical studies translated well to the human experience.' ART26.12 is the first orally administered, selective, and peripherally restricted FABP5 inhibitor to enter human clinical evaluation. By targeting FABP5, ART26.12 modulates endogenous lipid signaling molecules that exert analgesic effects through established pathways, including TRPV1, PPAR alpha, and cannabinoid receptors, with additional mechanisms such as Nav1.8 under investigation. The chronic pain therapeutics market exceeded $97 billion globally in 2023 and is expected to surpass $159 billion by 20301, driven by the increasing prevalence of conditions such as neuropathic pain, arthritis, and fibromyalgia. Despite the scale of the market, innovation remains sparse—particularly for non-opioid therapies. As part of the U.S Food and Drug Administration's Overdose Prevention Framework, the Agency has issued draft guidance aimed at encouraging the development of non-opioid analgesics for pain. ART26.12 is positioned to fill this gap with an innovative mechanism of action and favorable safety profile. A Multiple Ascending Dose study to further evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year. About ART26.12 ART26.12, Artelo's lead FABP5 inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). FABPs are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in several pathologies. In addition to ART26.12 in CIPN, Artelo's extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, anxiety disorders, and psoriasis. ART26.12 has been included in Helping to End Addiction Long-term® (HEAL) Initiative's Preclinical Screening Platform for Pain program of the U.S. National Institutes of Health. The HEAL program is dedicated to advancing non-opioid solutions to pain and curbing opioid use disorder. 1 About Artelo Biosciences Artelo Biosciences, Inc. is a clinical-stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, dermatologic conditions, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading-edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at and X: @ArteloBio. Forward-Looking StatementsInvestor Relations Contact: Crescendo Communications, LLC Tel: 212-671-1020 Email: [email protected]
Yahoo
2 hours ago
- Yahoo
Wearable and Non-Invasive Technologies Set to Revolutionize the $37.5 Bn Market
The Global Diabetes Testing System Market, valued at USD 21.48 Billion in 2025, is projected to reach USD 33.19 Billion by 2034, growing at a CAGR of 6.4%. With rising diabetes prevalence, demand for innovative and user-friendly diagnostic solutions, like CGMs and AI-driven systems, is surging. North America dominates the market, while Asia-Pacific sees rapid expansion. Key trends include wearable technology, minimally invasive methods, and digital health integration, enhancing diabetes management. Diabetes Testing System Market Dublin, June 30, 2025 (GLOBE NEWSWIRE) -- The "Diabetes Testing System Market Size, Share, Trends, Analysis, and Forecast 2025-2034 | Global Industry Growth, Competitive Landscape, Opportunities, and Challenges" has been added to Global Diabetes Testing System Market is poised for significant growth, with its size valued at USD 21.48 billion in 2025. Anticipated to expand at a CAGR of 6.4%, the market is projected to reach USD 33.19 billion by 2034. Key factors propelling this growth include aging populations, sedentary lifestyles, rising obesity rates, and increased incidence of both Type 1 and Type 2 diabetes. Diabetes testing systems, crucial to the healthcare ecosystem, encompass blood glucose meters, continuous glucose monitoring (CGM) devices, test strips, lancets, and advanced digital platforms. These tools collectively facilitate effective diabetes management by delivering real-time, user-friendly testing solutions. Technological advancements in wearable devices, minimally invasive sampling, and digital health integration are reshaping diabetes management across healthcare settings. Notably, North America leads the market, bolstered by robust healthcare infrastructure, favorable reimbursement policies, and high disease management awareness. Meanwhile, Asia-Pacific experiences rapid growth due to improving healthcare access and urbanization, alongside burgeoning diabetes cases. The competitive landscape is marked by innovation and strategic initiatives, with companies launching connected devices offering real-time monitoring, mobile app integration, and remote physician access. A focus on non-invasive technology, AI-driven insights, and compact systems for personalized care defines current market dynamics. Future success hinges on regulatory trends, affordability, and patient-centric design innovations. Key Takeaways - Diabetes Testing System Market: Rising diabetes prevalence drives demand for accurate and accessible self-monitoring and clinical testing systems. Blood glucose meters and CGMs dominate the technology landscape in diabetes testing. Next-gen CGMs equipped with real-time data, Bluetooth connectivity, and smartphone integration enhance glucose tracking. Minimally invasive and needle-free systems are emerging to boost patient compliance and convenience. AI-driven analytics and personalized alerts enhance proactive glucose management and complication prevention. Cloud-based platforms promote data sharing between patients, caregivers, and clinicians for remote diabetes management. Challenges entail pricing pressure, regulatory approvals, and the demand for improved accuracy and calibration-free solutions. Key Attributes: Report Attribute Details No. of Pages 150 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $21.48 Billion Forecasted Market Value (USD) by 2034 $37.54 Billion Compound Annual Growth Rate 6.4% Regions Covered Global Market Segmentation: By Product: Blood Glucose Monitors, Continuous Glucose Monitoring Systems, Test Strips. By Application: Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes. By End User: Hospitals, Home Care, Diagnostic Centers. By Technology: Self-Monitoring, Continuous Monitoring, Smart Device Integration. By Distribution Channel: Online Retail, Pharmacies, Hospital Distributors. By Geography: North America, Europe, Asia-Pacific, Middle East and Africa, South and Central America. Companies Featured Abbott Laboratories Roche Diabetes Care Dexcom, Inc. Medtronic plc Becton, Dickinson and Company Ascensia Diabetes Care LifeScan, Inc. Senseonics Holdings, Inc. ARKRAY, Inc. Nova Biomedical Corporation Ypsomed Holding AG GlucoMe Ltd. Nipro Corporation Terumo Corporation AgaMatrix, Inc. For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Diabetes Testing System Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Banking and Payments Expert Joins FTI Consulting as Senior Managing Director
WASHINGTON, D.C., June 30, 2025 (GLOBE NEWSWIRE) -- FTI Consulting, Inc. (NYSE: FCN) today announced the appointment of banking and payments expert Christopher Allen as a Senior Managing Director in the Financial Services practice within the Forensic and Litigation Consulting segment. Mr. Allen, who is based in Charlotte, has more than 30 years of experience in financial services, in both industry and advisory positions, supporting payment strategy, customer experience and operations modernization. In his role at FTI Consulting, Mr. Allen will help banks, payment intermediaries and fintechs modernize products, core operations, processes and underlying technology to drive value and enhance customer experience. Prior to joining FTI Consulting, Mr. Allen was the Payments Sector Lead at a Big Four firm, focusing on digital and product strategy, technology platform integration and operation transformation. Prior to his advisory roles, Mr. Allen held positions at major financial institutions including MasterCard International, JPMorgan Chase and US Bank, where he managed consumer and small business transaction products. 'We're seeing a major transition in the payments space as financial institutions leverage new technologies to upgrade legacy systems in order to meet regulatory demands, increase resilience and improve operations,' said Stella Mendes, Global Leader of the Financial Services practice within the Forensic and Litigation Consulting segment at FTI Consulting. 'Chris knows first-hand the impact inefficient processes can have on an institution and how to apply the right technologies to find solutions to those challenges.' Commenting on his appointment, Mr. Allen said, 'The payments sector is undergoing significant change as consumers, businesses and governments are seeking to reduce friction in the value chain, modernize payments technologies and deliver a greatly improved customer experience. FTI Consulting boasts a vast network of experts with hands-on knowledge, and I look forward to joining my colleagues as we work to create value for our clients.' Mr. Allen's appointment is the latest to the Financial Services practice as part of FTI Consulting's continued investment in client service offerings, following the recent appointment of seven senior professionals within the Forensic and Litigation Consulting segment. Professionals within the Financial Services practice advise banks and financial institutions across the business cycle, providing consumer financial services, risk management, regulatory compliance and enforcement advisory, and more. About FTI Consulting FTI Consulting, Inc. is a leading global expert firm for organizations facing crisis and transformation, with more than 8,100 employees located in 33 countries and territories as of March 31, 2025. In certain jurisdictions, FTI Consulting's services are provided through distinct legal entities that are separately capitalized and independently managed. The Company generated $3.70 billion in revenues during fiscal year 2024. More information can be found at FTI Consulting, Inc. 555 12th Street NW Washington, DC 20004 +1.202.312.9100 Investor Contact: Mollie Hawkes +1.617.747.1791 Media Contact: Sam Ford+ while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
